SPRAVATO is a prescription medication to be used alongside an oral antidepressant for best results. Patients self administer SPRAVATO nasal spray in-clinic and are monitored by staff for a two hour period of observation time. 

Esketamine has the potential to distort one's perception of the world around then while under the influence of the medication. This is why we administer in the clinic and monitor patients for two hours. 

Research studies show that FDA-approved Spravato treatment for depression is highly effective and rapid-acting.

Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray.

Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant.